RNXT Stock Summary and Trading Ideas (Renovorx | NASDAQ:RNXT)

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Renovorx trades on the NASDAQ stock market under the symbol RNXT.

As of June 12, 2026, RNXT stock price declined to $0.84 with 121,765 million shares trading.

RNXT has a beta of 0.64, meaning it tends to be less sensitive to market movements. RNXT has a correlation of 0.01 to the broad based SPY ETF.

RNXT has a market cap of $38.05 million. This is considered a Sub-Micro Cap stock.

Last quarter Renovorx reported $563,000 in Revenue and -$.08 earnings per share. This beat revenue expectation by $92,400 and met earnings estimates .

In the last 3 years, RNXT traded as high as $3.29 and as low as $.53.

The top ETF exchange traded funds that RNXT belongs to (by Net Assets): VTI, VXF.

RNXT has underperformed the market in the last year with a price return of -38.0% while the SPY ETF gained +24.6%. RNXT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +6.1% and -14.7%, respectively, while the SPY returned +9.9% and -1.7%, respectively.

RNXT support price is $.81 and resistance is $.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RNXT shares will trade within this expected range on the day.